Lean tissue mass is associated with adverse outcomes across different stages of chronic kidney disease: a systematic review and meta-analysis

瘦组织量与慢性肾脏病不同阶段的不良预后相关:一项系统评价和荟萃分析

阅读:1

Abstract

In chronic kidney disease it is hypothesised that the association between loss of lean tissue mass (LLTM) and mortality is purely a function of multimorbidity. We conducted a systematic review in CKD patients to quantify the strength of association between LLTM and mortality or frailty surrogates, including hospitalisation and quality of life (QoL). Muscle mass was estimated using different whole-body bioimpedance methods (BI-MM). Searches of electronic databases identified 132 studies for inclusion (147542 dialysis patients; 15378 CKD(G3−5) patients; 356 kidney transplant recipients [KTR], with 14429 deaths). From 67 studies reporting unadjusted analyses, 52 (78%) demonstrated associations between LLTM and mortality. In 80 studies reporting analyses adjusting for age, sex, and multimorbidity, 59 (74% overall: 74, 67 and 100% in dialysis, CKD, and KTR studies respectively) reported an association. Meta-analysis of dialysis studies reporting adjusted survival analyses found each degree decrease in phase angle or a lean tissue index < 10th percentile was associated with a 92 and 49% higher hazard of mortality respectively. In studies reporting hospitalisation and QoL measures, 63 and 76% reported associations with BI-MM respectively. In conclusion, having accounted for multimorbidity, LLTM remained associated with mortality and frailty surrogates in CKD, irrespective of the BI-MM method used. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1038/s41598-025-34111-2.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。